June 15, 2026 —
Intellia Therapeutics reported additional Phase 3 data showing that lonvoguran ziclumeran, or lonvo-z, met key secondary endpoints in patients with hereditary angioedema, or HAE, with both statistical and clinical significance. The data were presented at the European Academy of Allergy and Clinical Immunology Annual Congress 2026 and simultaneously published in The New England Journal of Medicine.
Lonvo-z is an investigational in vivo CRISPR gene-editing therapy designed as a one-time treatment for HAE. The therapy is intended to permanently reduce kallikrein activity by inactivating the KLKB1 gene, which encodes plasma kallikrein. Kallikrein contributes to the production of bradykinin, a key mediator of swelling attacks in HAE.
HAE is a rare genetic disease characterized by recurrent, unpredictable, and potentially life-threatening swelling episodes affecting the face, limbs, gastrointestinal tract, and airways. Current approved therapies can reduce attack frequency, but most require chronic administration. Lonvo-z is designed to provide durable disease control after a single treatment.
The Phase 3 HAELO study randomized 80 patients with HAE. As previously reported, lonvo-z achieved the study’s primary endpoint, showing an 87% reduction in mean monthly HAE attacks compared with placebo during weeks 5 through 28. During the six-month efficacy evaluation period, 62% of patients treated with lonvo-z were both attack-free and treatment-free, compared with 11% of patients in the placebo group.
The newly reported secondary endpoint data showed an 89% reduction in the monthly rate of attacks requiring on-demand treatment from weeks 5 through 28. Lonvo-z also produced a 91% reduction in the monthly rate of moderate to severe attacks during the same period.
Patient-reported outcomes also improved. Intellia reported a 17-point improvement by week 28 in the Angioedema Quality of Life score, or AE-QoL. A 6-point reduction is generally considered a clinically meaningful improvement, suggesting that the treatment may have meaningful impact beyond attack reduction.
The safety profile was described as favorable through week 28. Treatment-emergent adverse events were mild or moderate and included headache, fatigue, back pain, and upper respiratory tract infection. Intellia also reported reductions in attack rates across evaluated subgroups, regardless of age or prior use of long-term prophylaxis therapy.
The data represent one of the most advanced clinical readouts to date for in vivo CRISPR gene editing. Unlike ex vivo gene-edited cell therapies, lonvo-z is administered directly to the patient and is designed to edit the target gene inside the body. If approved, it could represent a new treatment model for HAE by reducing or eliminating the need for lifelong prophylactic therapy.
Lonvo-z is currently under a rolling Biologics License Application submission, with a potential launch expected in the first half of 2027. If approved, it would enter a treatment landscape that includes chronic therapies such as Ionis Pharmaceuticals’ Dawnzera, Takeda’s Takhzyro, and BioCryst Pharmaceuticals’ Orladeyo. Its key differentiation is the potential for durable control after a single in vivo gene-editing treatment.
While the Phase 3 results are promising, the published study also noted limitations, including a relatively small patient population, limited follow-up, and a carefully selected patient cohort. Longer-term data will be important to assess durability, safety, and real-world clinical benefit.
